Monday, May 08, 2023

COVID-19 Vaccine Effectiveness Drops Near Zero Within Months

The effectiveness of COVID-19 vaccines fell below 20 percent a few months after vaccination, with booster shots seeing effectiveness drop below 30 percent.

The review, published in the JAMA Network journal on May 3, analyzed 40 studies estimating vaccine effectiveness (VE) over time against laboratory-confirmed COVID-19 infection and symptomatic disease. The studies were selected from 799 original articles, 149 reviews published in peer-reviewed journals, and 35 preprints. The review found that the vaccine effectiveness of a primary vaccination cycle against the Omicron infection and symptomatic disease was lower than 20 percent at 6 months from the administration of the last dose.

Booster doses restored vaccine effectiveness to levels similar to those seen after administration of the primacy cycle dose. However, nine months after the booster dose, vaccine effectiveness against Omicron was found to be lower than 30 percent against infection and symptomatic disease.

“The half-life of VE against symptomatic infection was estimated to be 87 days for Omicron compared with 316 days for Delta. Similar waning rates of VE were found for different age segments of the population.”

“These findings suggest that the effectiveness of COVID-19 vaccines against laboratory-confirmed Omicron or Delta infection and symptomatic disease rapidly wanes over time after the primary vaccination cycle and booster dose,” the study said.

“Putting together the bulk of available evidence on the waning of VE over time against COVID-19 variants has crucial implications for future interventions and vaccination programs.”

Effectiveness by Vaccine Brand

Vaccine effectiveness against Omicron infection was 44.4 percent a month after the completion of the primary vaccination cycle. This fell to 20.7 percent at six months and then to 13.4 percent at nine months. Vaccine effectiveness was found to be higher against the Delta variant as compared to the Omicron variant.

“Pooled estimates of VE after any primary vaccination cycle against symptomatic disease after Omicron infection show a marked waning over time,” the study stated.

Effectiveness against symptomatic disease fell from 52.8 percent a month after completion of the primary vaccination cycle to 14.3 percent at six months and 8.9 percent at nine months.

“Our estimates suggest that the initial VE could be different depending on the vaccine product, with higher VE found at one month from the second dose administration for Moderna and Pfizer-BioNTech compared with AstraZeneca and Sinovac.”

With regard to age, vaccine effectiveness was found to be similar in younger and older age groups against the Omicron variant infection.

No “significant differences” were observed between the two age groups regarding vaccine effectiveness against Delta variant infection. “A significantly lower VE was found for both age groups for Omicron compared with Delta,” it stated.

Vaccine Harms

COVID-19 vaccines have been known to lead to several medical conditions. One study that examined 9,500 women found that those who had taken COVID-19 shots had a slightly higher risk of heavier menstrual bleeding. In the study, 40 out of 1,000 women saw bleeding increase after just a single dose of a vaccine.

Earlier research from the same team had found that the length of the menstrual cycle increased by 3.7 days on average among women who had taken two doses of COVID-19 vaccines compared to those who hadn’t taken a shot.

According to a study from February published in the British Medical Journal, heart failure and deaths have occurred among those who have taken COVID-19 shots.

Researchers found that more people experienced myocarditis after COVID-19 vaccination than after being infected by the virus. Myocarditis is a type of heart inflammation.

A March report from Phinance Technologies, a global macro investment firm co-founded by former BlackRock portfolio manager Edward Dowd, estimates that COVID-19 vaccine damages in the United States resulted in more than 26 million people being injured last year, with such injuries costing almost $150 billion to the economy.

Misleading Effectiveness Claims, Compensation for Injuries
Texas Attorney General Ken Paxton is also looking at whether Pfizer, Moderna, and Johnson & Johnson misrepresented the efficacy of their COVID-19 vaccines.

According to Paxton, the companies may have violated the Texas Deceptive Trade Practices Act, which bars people intending to sell a product from disseminating a statement that they know “materially misrepresents the cost or character of tangible personal property, a security, service, or anything he may offer.”

It also bans representing that a product is “of a particular standard, quality, or grade … if they are of another.”

Paxton has asked the three companies to submit relevant documents and information, including any concerns with regard to the vaccine trials.

Meanwhile, letters from U.S. officials that were reviewed by The Epoch Times show that authorities rejected multiple individuals who had sought compensation for injuries suffered as a result of taking a COVID-19 shot despite diagnoses from doctors.

One such individual is agricultural pilot Cody Flint who began suffering from adverse reactions to Pfizer’s COVID-19 vaccine after taking a shot. Four doctors confirmed that his medical complication, including experiencing intense head pressure, were linked to the COVID-19 vaccine.

Flint sent the medical files to the U.S. Countermeasures Injury Compensation Program (CICP), which is tasked with compensating people who prove that they were injured due to getting vaccinated against COVID-19.

However, CICP rejected Flint’s claim, saying that it did not find the “requisite evidence” necessary to prove that his health issues were caused by the Pfizer vaccine.


Delirium Cases in the Elderly After COVID-19 Vaccination

The elderly are a particularly vulnerable population to COVID-19 infection so they were prioritized when it came to the COVID-19 vaccination. However, we now know that COVID-19 vaccines might also on rare occasions cause some adverse events. One of these that has been reported is delirium, and it appears to affect mainly the elderly. TrialSite previously reported on the neurological side effects of COVID-19 vaccines. This article will summarize a case series that reports delirium in the elderly after COVID-19 vaccines.

Delirium is characterized by poor concentration, disorientation, paranoia, memory loss, agitation and sometimes hallucinations. The presentation of these symptoms varies from person to person and symptoms may also involve sleep problems and behavioral disruptions such as hyper or hypoactivity. The symptoms of delirium should not be explained by any other neurocognitive condition but rather by an underlying medical problem. Causes of delirium can vary widely from stress to anesthesia due to surgery.

The case series

Researchers conducted the study at a nursing home (NH) with 514 beds during the period of COVID-19 vaccination for the residents. Participants were 70 years and older. Participants who had positive COVID-19 results or who had a history of alcoholism, were nonverbal, were deaf or blind, or could not speak English were excluded.

After the participants had been recruited, they were examined for conditions that could cause a change in their health status. The study considered vaccination against COVID-19 as a condition that might affect the health status. A day after the vaccination, participants were tested using the Confusion Assessment Method-Severity (CAM-S) instrument, a method used to assess the severity of delirium symptoms. A random sample was selected based on the results of CAM-S. After the initial selection, participants completed a more structured assessment involving the following:

Severe Impairment Battery?8 (SIB?8), a brief assessment method for people with severe Alzheimer’s disease.

The Montreal Cognitive Assessment (MoCA), a screening test for mild cognitive impairment (MCI). This condition is characterized by a cognitive decline that does not affect an individual’s daily functioning but is still noticeable to others.

The Confusion Assessment Method (CAM), a method to use to identify delirium.

Researchers diagnosed delirium using the criteria listed in the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM?5), a reference manual for the diagnosis of mental illness and neurocognitive disorders, based on the residents’ test results at baseline and after vaccination. The participants were diagnosed either with delirium or subsyndromal delirium, defined as a condition where one shows delirium symptoms but does not meet the DSM-5 criteria.

Demographic information was also collected from the participants including:

Previous delirium history
Presence of dementia
Presence of MCI


The study involved 40 participants; 39 of them had their third dose of the COVID-19 vaccine and one received the second dose.

Demographic information was as follows:

The average age of the participants was 82 years.
45% of them were males.

13% of the ethnicity was Latino/Hispanic and non-Whites were 43%.

65% of the participants had dementia and 35% had MCI.

18% of the participants had a previous history of delirium.

Out of the 40 participants, 10% showed symptoms; three showed delirium (7.5%) a day after the vaccination and one participant was diagnosed with subsyndromal delirium (2.5%). A day after the vaccination, these four participants had increased CAM-S scores and decreased MoCA scores compared to their baseline scores.

Within two weeks participants’ scores went back to normal and delirium was resolved. SIB-8 scores also showed the same pattern.

Among 26 people with dementia, three (26%) experienced delirium; among 14 cases without dementia, one (7%) experienced delirium, among seven cases of participants with a previous history of delirium, none experienced delirium after the COVID-19 vaccine, and among 33 participants without a previous delirium history, four (12%) experienced delirium.




No comments: